NCT04664972View on ClinicalTrials.gov

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

PHASE2CompletedINTERVENTIONAL

Enrollment

212

Participants

Timeline

Start Date

November 23, 2018

Primary Completion Date

November 26, 2022

Study Completion Date

November 26, 2022

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Docetaxel +doxorubicin+ cyclophosphamide

The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.

DRUG

Docetaxel +Cisplatin

The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.

Trial Locations (1)

450008

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV

NCT04664972 - Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC | Biotech Hunter | Biotech Hunter